Mazor Robotics Ltd. (NASDAQCM:MZOR; TASE:MZOR), the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today that it has received its first order for a Renaissance system from Cordamed Biomedical Engineering Inc., its distribution partner in Turkey. This represents the first Renaissance system order in Turkey, and Cordamed will install the system at a prominent hospital in Istanbul.
“Our strategy of working with distributors is demonstrating tangible results, allowing us to expand our presence in key markets,” commented Ori Hadomi, Mazor’s Chief Executive Officer. “Our Renaissance system enables hospitals to improve patient care with a leading technology, thus raising the standard of the care.”
“The Cordamed team is highly skilled and motivated to ensure the healthcare system throughout Turkey is utilizing the latest technologies to provide better surgery outcomes,” commented Bayram Kose, Chief Executive Officer of Cordamed. “The clinical success to date of the Renaissance system could create additional opportunities in Turkey as healthcare facilities seek to raise the standard of care.”
Cordamed has been focused on the minimally invasive surgery (MIS) market since 2006, representing a new generation of medical device companies that have developed leading technology products. Through its analytical experiences in biomedical engineering and a highly experienced post-sales assistance team, it has exclusive distribution rights for most of the robotic surgical systems that improve the quality of healthcare services standards in Turkey.
Mazor Robotics is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit
, the content of which does not form a part of this press release.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expansion of Mazor into key markets, the clinical and economic benefits of Renaissance, additional opportunities in Turkey, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC), including those discussed under the heading "Risk Factors" in Mazor’s registration statement on Form F-1 filed with the SEC on and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.